HDAC9 and neoplasm: In fact, one of the common problems associated with the currently available HDAC inhibitors is their low degree of target HDAC selectivity against other classes of HDACs as well as closely related members of the same class, such as HDAC4, HDAC5, HDAC7, and HDAC9, with different tumor-suppressor functions.